FDA grants praliciguat (IW-1973) fast-track status for heart failure reserved for blood-borne scores

recently, IronwoodPharmaceuticals(Inc.)
(theFDA) has granted praliciguat (IW-1973) fast-track status for the treatment of heart failure (HFpEF) retained by the blood-borne fractionpraliciguat
praliciguat is an oral, soluble bird nucleotide cyclase (sGC) stimulant, discovered and fully controlled by Ironwood, and is currently in Phase II clinical (NCT0325485) to develop potential treatments for diabetic nephropathy and HfEFpraliciguat has the potential to improve nitric oxide (NO) signaling to address the potential causes of these destructive diseases, improve vascular and metabolic function, and reduce inflammation and fibrosis associated with these diseasesIronwood, a pioneer and leader in cGMP, has launched a marketedproduct(linaclotide, Linalopeptide), a bird nucleotide cyclase-C (GC-C) agonist that binds to and localizes GC-C receptors on the surface of the small intestine epidermal tube cavityThe activation of GC-C leads to an increase in intracellular and extracellular cGMP concentrations, and intracellular cGMP elevation stimulates the secretion of chlorine and bicarbonate ions into the intestinal cavity, causing the small intestine secretion to increase and accelerate passageso far, Linzess has been approved for the treatment of constipation-type irritable bowel syndrome (IBS-C) and chronic isophalsis (CIC)Currently, Ironwood has a number of soluble bird nucleotide cyclase (sGC) stimulators in its pipelinesGC plays an important role in regulating a variety of physiological processes, and sGC disorders may be associated with a variety of serious diseases Ironwood's sGC stimulator is believed to improve blood flow and metabolism, reduce inflammation and fibrosis by modulatenite nitric oxide/sGC/cyclogacid glycolic acid (NO/sGC/cGMP) signaling pathways